Results from randomized clinical outcomes trials (RCTs) and meta-analyses of patients with heart failure (HF) have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular (CV) outcomes in patients with chronic HF irrespective of diabetes status and across a wide spectrum of left ventricular ejection fraction [1–7]. This evidence concerns the gene SLC5A2 and heart failure.